UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 2, 2012

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)

Delaware	94-3023969
(State or Other Jurisdiction of Incorporation)	(I.R.S. Employer Identification No.)

932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On August 2, 2012, PDL BioPharma, Inc. (the Company) issued a press release announcing the financial results for the second quarter ended June 30, 2012. A copy of this earnings release is attached hereto as Exhibit 99.1. The Company will host an earnings call and webcast on August 2, 2012, during which the Company will discuss its financial results for the second quarter ended June 30, 2012.

Item 7.01 Regulation FD Disclosure.

Presentation Materials

On August 2, 2012, the Company posted to its website a set of presentation materials that it will use during its earnings call and webcast to assist participants with understanding the Company's financial results. A copy of this presentation is attached hereto at Exhibit 99.2

Information Sheet

On August 2, 2012, the Company distributed to analysts covering the Company's securities a summary of certain information regarding the Company's net income, dividends, convertible notes, and licensed product development and sales (the Information Sheet) to assist those analysts in valuing the Company's securities. Copies of the Information Sheet and its associated tables are attached hereto as Exhibits 99.3 and 99.4, respectively.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, the information in this report, including the exhibits, is furnished pursuant to Items 2.02 and 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Cautionary Statements

This filing and its exhibits include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company's royalty assets or business are disclosed in the "Risk Factors" contained in the Company's Annual Report on Form 10-K, as updated by subsequent quarterly reports, filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Press Release
99.2	Presentation
99.3	Information Sheet
99.4	Tables to Information Sheet

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)

By: /s/ Bruce W. Tomlinson
Bruce W. Tomlinson
Vice President and
Chief Financial Officer

Dated: August 2, 2012

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release
99.2	Presentation
99.3	Information Sheet
99.4	Tables to Information Sheet

Exhibit 99.1

Contacts:
Bruce Tomlinson
PDL BioPharma, Inc.
775-832-8500
bruce.tomlinson@pdl.com

Jennifer Williams
Cook Williams
Communications
360-668-3701
jennifer@cwcomm.org

PDL BioPharma Announces Second Quarter 2012 Financial Results

INCLINE VILLAGE, NV, August 2, 2012 – PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2012.

Royalty revenues for the second quarter of 2012 increased three percent to $125.9 million from $122.1 million reported in the second quarter of 2011. For the first six months of 2012, royalty revenues increased four percent to $203.2 million from $195.5 million reported in the comparable period of 2011. Total revenue for the first six months of 2012 of $203.2 million is one percent lower than total revenue for the first six months of 2011 of $205.5 million, as a result of a one-time settlement payment of $10 million from UCB Pharma received in 2011.

Royalty revenues for the second quarter of 2012 are based on first quarter 2012 product sales by PDL's licensees. The growth in royalty revenues was driven primarily by increased royalties from first quarter 2012 sales of Herceptin®, which is marketed by Genentech and Roche, Lucentis® and Xolair®, which are marketed by Genentech and Novartis, and Tysabri®, which is marketed by Elan and Biogen Idec. Royalty revenue for the second quarter is net of payments made under PDL's February 2011 settlement agreement with Novartis Pharma AG.

General and administrative expenses for the second quarter of 2012 were $5.1 million, compared with $3.8 million in the same quarter of 2011. For the six months ended June 30, 2012, general and administrative expenses were $12.1 million compared to $9.6 million in the comparable period of 2011. The increase in expenses for both the quarter and six months ended June 30, 2012, is primarily due to expenses related to efforts to acquire new revenue generating assets, compensation related expenses and legal expenses.
Net income for the second quarter of 2012 was $73.5 million, or $0.52 per diluted share, as compared with net income of $70.0 million, or $0.38 per diluted share, in the same quarter of 2011. Net income for the first six months of 2012 was $113.7 million, or $0.80 per diluted share, as compared with net income of $114.5 million, or $0.63 per diluted share, in the same period of 2011. Adjusting for the non-cash interest expense associated with the Series 2012 Notes and 3.75% Convertible Senior Notes due 2015 (May 2015 Notes), non-GAAP net income for the second quarter of 2012 was $75.1 million, or $0.53 per diluted share, compared to non-GAAP net income of $70.8 million, or $0.39 per diluted share for the same period of 2011. Non-GAAP net income for the first six months of 2012 was $116.9 million, or $0.82 per diluted share, compared to non-GAAP net income of $115.4 million, or $0.63 per diluted share for the same period of 2011. The non-GAAP net income adjustment for the three and six month period of 2011 includes an adjustment for the convertible note repurchase transaction in June 2011. We are presenting non-GAAP measures because we believe this exclusion facilitates comparison to PDL's cash operating results.

Net cash provided by operating activities in the first six months of 2012 was $122.8 million, compared with $87.9 million for the first six months of 2011. At June 30, 2012, PDL had cash, cash equivalents and investments of $229.3 million, compared with $227.9 million at December 31, 2011.

Recent Developments

Credit Agreement with Merus Labs International, Inc.
In July 2012, PDL loaned $35 million to Merus Labs International, Inc. (Merus Labs) in connection with its acquisition of a commercial-stage pharmaceutical product and related assets (the Assets). In addition, PDL agreed to provide a $20 million letter of credit on behalf of Merus Labs that the seller of the Assets may draw upon to satisfy the remaining $20 million purchase price obligation on July 11, 2013. Draws on the Letter of Credit will be funded from the proceeds of an additional loan to Merus Labs. Outstanding borrowings under the July 2012 loan bear interest at the rate of 13.5% per annum and outstanding borrowings as a result of draws on the Letter of Credit bear interest at the rate of 14.0% per annum. Merus Labs is required to make four periodic principal payments in respect to the July 2012 loan, with repayment of the remaining principal balance of all loans due on March 31, 2015. The borrowings are subject to mandatory prepayments upon certain asset dispositions or debt issuances under the terms set forth in the credit agreement. The loan is secured by substantially all of the assets of Merus Labs.

Perjeta™
On June 8, 2012, Genentech announced that the U.S. Food and Drug Administration (FDA) approved Perjeta (pertuzumab). Perjeta is approved in combination with Herceptin and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Genentech notified PDL on June 18, 2012, that Perjeta is a licensed product. PDL will receive royalties on sales of Perjeta in the quarter following the first quarter of Perjeta sales in accordance with Genentech's license agreements with PDL.

2012 Dividends
On January 18, 2012, PDL's Board of Directors declared regular quarterly dividends of $0.15 per share of common stock, payable on March 14, June 14, September 14 and December 14 of 2012 to stockholders of record on March 7, June 7, September 7 and December 7 of 2012, the record dates for each of the dividend payments, respectively. On June 14, 2012, PDL paid the second quarterly dividend to stockholders of record totaling $21 million using earnings generated in the second quarter of 2012.

Revenue Guidance for 2012
As previously announced, PDL will continue to provide revenue guidance for each quarter in the third month of that quarter. Third quarter 2012 revenue guidance will be provided in September.

Conference Call Details
PDL will hold a conference call to discuss financial results at 4:30 p.m. ET today, August 2, 2012.

To access the live conference call via phone, please dial (877) 677-9122 from the United States and Canada or (708) 290-1401 internationally. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through August 9, 2012, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 12377244.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. A slide presentation relating to the call will be available via the webcast link on the PDL website.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new revenue generating assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.

Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new royalty bearing assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission and updated by subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2012	**2011**	**2012**	**2011**
Revenues:				
Royalties	$ 125,904	$ 122,127	$ 203,248	$ 195,463
License and other	-	-	-	10,000
Total revenues	125,904	122,127	203,248	205,463
General and administrative expenses	5,145	3,776	12,090	9,555
Operating income	120,759	118,351	191,158	195,908
Non-operating expense, net				
Loss on repurchase of convertible notes	-	(766)	-	(766)
Interest and other income, net	428	157	518	332
Interest expense	(7,872)	(9,780)	(16,573)	(18,934)
Total non-operating expense, net	(7,444)	(10,389)	(16,055)	(19,368)
Income before income taxes	113,315	107,962	175,103	176,540
Income tax expense	39,813	37,976	61,417	62,009
Net income	$ 73,502	$ 69,986	$ 113,686	$ 114,531
Net income per share				
Basic	$ 0.53	$ 0.50	$ 0.81	$ 0.82
Diluted	$ 0.52	$ 0.38	$ 0.80	$ 0.63
Cash dividends declared per common share	$ -	$ -	$ 0.60	$ 0.60
Weighted average shares outstanding				
Basic	139,683	139,650	139,681	139,645
Diluted	142,213	186,060	142,890	186,055

PDL BIOPHARMA, INC.
RECONCILIATION OF GAAP FINANCIAL INFORMATION TO NON-GAAP
(Unaudited)
(In thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2012	**2011**	**2012**	**2011**
Net income	$ 73,502	$ 69,986	$ 113,686	$ 114,531
Add back:				
Loss on repurchase of convertible debt, net of estimated taxes	-	498	-	498
Amortization of debt discount on Series 2012 Notes and May 2015 Notes, net of estimated taxes	1,642	337	3,238	337
Non-GAAP net income	75,144	70,821	116,924	115,366
Add back interest expense for convertible notes, net of estimated taxes	6	1,275	33	2,549
Non-GAAP income used to compute non-GAAP net income per diluted share	$ 75,150	$ 72,096	$ 116,957	$ 117,915
Shares used to compute non-GAAP net income per diluted share	142,213	186,060	142,890	186,055
Non-GAAP net income per diluted share	$ 0.53	$ 0.39	$ 0.82	$ 0.63

PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(Unaudited)
(In thousands)

	June 30, 2012	December 31, 2011
Cash, cash equivalents and investments	$ 229,333	$ 227,946
Total assets	$ 259,829	$ 269,471
Non-recourse notes payable	$ 22,738	$ 93,370
Convertible notes payable	$ 304,767	$ 316,615
Total stockholders' deficit	$ (161,114)	$ (204,273)

PDL BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW DATA
(Unaudited)
(In thousands)

	Six Months Ended June 30,	
	2012	2011
Net income	$ 113,686	$ 114,531
Adjustments to reconcile net income to net cash provided by operating activities	12,779	24,941
Changes in assets and liabilities	(3,672)	(51,549)
Net cash provided by operating activities	$ 122,793	$ 87,923

PDL BioPharma™

Second Quarter 2012 Financial Results Conference Call

August 2, 2012

Forward Looking Statements

This presentation contains forward-looking statements, including PDL's expectations with respect to its future royalty revenues, expenses, net income, and cash provided by operating activities.

Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

- The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
- The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
- The ability of PDL's licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
- The productivity of acquired revenue generating assets is uncertain and may not fulfill our revenue forecasts made at the time of execution;
- Changes in any of the assumptions on which PDL's projected revenues are based;
- Changes in foreign currency rates;
- Positive or negative results in PDL's attempt to acquire revenue related assets;
- The outcome of pending litigation or disputes, including PDL's current dispute with Genentech related to ex-U.S. sales of Genentech licensed products; and
- The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this presentation are qualified in their entirety by this cautionary statement.

PDL BioPharma

New Licensed Product: Perjeta

- **Approved**
  - June 8, 2012
- **Indication**
  - Pertuzumab + Herceptin + docetaxel for first line treatment of metastatic HER2+ breast cancer
  - Pertuzumab + Herceptin + docetaxel improved PFS by 6.1 months in first line treatment of HER2+ breast cancer patients compared to placebo + Herceptin + docetaxel (18.5 months v. 12.4 months, respectively)
  - On June 22, 2012, Genentech and Roche announced that Perjeta met the secondary endpoint of overall survival in its Phase 3 trial
- **Launched**
  - June 9, 2012
- **Price**
  - $5,900/month
- **Royalties**
  - Genentech and Roche have notified PDL that it is a licensed product
  - Royalties due beginning in 3Q12 on sales that occurred in 2Q12
  - Subject to tiered royalty scheme applicable to Avastin, Herceptin, Lucentis, and Xolair
- **Adjuvant Setting**
  - Phase 2 data showed patients on Perjeta, Herceptin and docetaxel in the adjuvant setting had a pathologic complete response or pCR of 45.8% compared to 29% for those HER2+ breast cancer patients receiving only Herceptin and docetaxel
  - Currently in Phase 3

PDL BioPharma

Revenue Generating Assets

- **PDL's Current Revenues**
  - PDL is paid royalties by licensees of its Queen et al patents
  - Last of Queen et al patents expire in December 2014
  - PDL will continue to be paid royalties thereafter on product made before patent expiration and sold after patent expiration
- **Investor Input: Dividends**
  - Investors have stated that they like the return generated by PDL's dividends
  - They have also expressed concern that PDL may cease paying dividends
  - Management has been evaluating new revenue generating assets
  - Indifferent as to therapeutic area or whether structure is royalty, debt or hybrid
  - Focus is on quality of revenue generating asset, likelihood of payment and return for PDL shareholders

PDL BioPharma

Merus Credit Agreement

- **Purpose**
  - Proceeds used to purchase the European and Canadian rights to manufacture, market, and sell Emselex® /Enablex® (Darifenacin) extended release tablets from Novartis
- **Amount**
  - Initial amount: $35 million
  - Additional amount: $20 million Letter of Credit which Merus may draw on to pay remaining purchase price of $20 million
- **Maturity**
  - March 2015
- **Interest Rate**
  - 13.5% per annum on outstanding principal
  - 14.0% per annum if $20 million Letter of Credit is drawn beginning when drawn
- **Security**
  - All assets of Merus

PDL BioPharma

Second Quarter 2012 Overview

	Quarter Ended June 30		Six Months Ended June 30	
	(In thousands, except per share amounts)			
	2012	2011	2012	2011
Royalty revenues	$ 125,904	$ 122,127	$ 203,248	$ 195,463
G&A Expenses	5,145	3,776	12,090	9,555
Operating income	120,759	118,351	191,158	195,908
Interest expense	(7,872)	(9,780)	(16,573)	(18,934)
Income before income taxes	113,315	107,962	175,103	176,540
Income tax expense	39,813	37,976	61,417	62,009
Net income	73,502	69,986	113,686	114,531
Net income per share - Basic	$0.53	$0.50	$0.81	$0.82
Net income per share - Diluted	$0.52	$0.38	$0.80	$0.63

	June 30, 2012	December 31, 2011
Cash, cash equivalents and investments	$229,333	$227,946
Total assets	$259,829	$269,471
Total debt carrying value	$327,505	$409,985

Convertible Note Conversion Rates

- In connection with the June 14, 2012 dividend payment, the conversion rates for our convertible notes increased as follows:

Convertible Notes	Conversion Rate per $1,000 Principal Amount	Approximate Conversion Price Per Common Share	Effective Date	Principal Balance Outstanding
May 2015 Notes	142.5217	$ 7.02	June 5, 2012	$ 155,250,000
Series 2012 Notes	162.885	$ 6.14	June 5, 2012	$ 179,000,000
February 2015 Notes	162.885	$ 6.14	June 8, 2012	$ 1,000,000

Question and Answer Session

PDL BioPharma, Inc.
Q2-2012
August 2, 2012

Following are some of the key points regarding PDL's second quarter 2012 financial and business results.

Net Income

- Net income for the second quarter of 2012 was $73.5 million, or $0.52 per diluted share, as compared with net income of $70.0 million, or $0.38 per diluted share, in the same quarter of 2011.

- Second quarter net income per diluted share is higher in 2012 when compared to 2011 due to increased revenue and the elimination of 44 million shares from the diluted earnings per share calculation after we restructured two of our convertible notes to "net share settle."

2012 Dividends

- We declared a regular, quarterly dividend of $0.15 per share of common stock payable on March 14, June 14, September 14 and December 14 to stockholders of record on March 7, June 7, September 7 and December 7.

- We paid $0.15 per share of common stock, or $21.0 million, on June 14, 2012 to our stockholders of record on June 7, 2012 as part of our regular, quarterly dividend policy for 2012.

Adjustments to Conversion Rates of Convertible Notes

- The conversion rate for our 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) was adjusted to 162.885 shares of common stock per $1,000 principal amount, or a conversion price of approximately $6.14 per share, effective June 8, 2012.

- The conversion rate for our 3.75% Senior Convertible Notes due May 1, 2015 (May 2015 Notes) was adjusted to 142.5217 shares of common stock per $1,000 principal amount, or a conversion price of approximately $7.02 per share, effective June 5, 2012.

- The conversion rate for our 2.875% Series 2012 Convertible Notes due February 15, 2015 (Series 2012 Notes) was adjusted to 162.885 shares of common stock per $1,000 principal amount, or a conversion price of approximately $6.14 per share, effective June 5, 2012.

Updates on Approved Royalty Bearing Products

Lucentis™ (ranibizumab):

- On Thursday, July 26th, FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted that safety and efficacy data support approval of the 0.3 mg and 0.5 mg doses of Lucentis for diabetic macular edema.
- Genentech and Roche are only seeking approval of the 0.3 mg dose.
- PDUFA date for this application for approval is August 10, 2012.
- Lucentis is already approved for this indication in EU.

Perjeta™ (pertuzumab):

- On June 8, 2012, Genentech and Roche announced the U.S. Food and Drug Administration (FDA) approval of Perjeta in combination with Herceptin and docetaxel for the first line treatment of patients with HER2+ metastatic breast cancer.
    - Perjeta launched the day after approval.
    - Price is $5,900 per month.
    - Genentech and Roche have notified PDL of its status as a licensed product.
    - PDL will begin receiving royalties in 3Q12 based on sales occuring in 2Q12.
    - Royalties will be subject to the tiered system applicable to Avastin, Herceptin, Lucentis and Xolair sales.
    - Genentech and Roche projected peak sales in excess of $1 billion annually for Perjeta.
- On June 22, 2012, Genentech and Roche announced that Perjeta met the secondary endpoint of OS in its Phase 3 trial.
- In the adjuvant setting, Phase 2 data showed patients on Perjeta, Herceptin and docetaxel had a pathologic complete response or pCR of 45.8% compared to 29% for those HER2+ breast cancer patients receiving only Herceptin and docetaxel.
    - Perjeta is currently being studied in Phase 3 in the adjuvant setting.

Updates on Select Development Stage Potential Royalty Bearing Products

BAPINEUZUMAB:

- On July 23, 2012, Pfizer reported that, in a Phase 3 clinical study using bapineuzumab to treat patients with mild-to-moderate Alzheimer's disease and carry the apolipoprotein E epsilon 4 (ApoE4) allele, bapineuzumab did not meet the trial's endpoints.
- In its Tuesday, July 31st earnings call, Pfizer disclosed that data from Phase 3 trial which enrolled non-apoe4 carriers is being analyzed and that the data will be presented in September.

SOLANEZUMAB:

- Lilly has advised that data from its two Phase 3 trials will be disclosed in 2H12 with many speculating that it will be presented at one or both of the Alzheimer's Disease conferences in the beginning and end of October.
- Lilly has said that it will stratify the patients by apoe4 carrier status when analyzing the results but it is not known how many patients with and without the apoe4 allele have been enrolled in the two trials.

Forward-looking Statements

This document contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new royalty bearing assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, and updated by subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

PDL BioPharma, Inc.
Q2-2012
August 2, 2012

Royalty Revenue by Product ($ in 000's) *

Avastin	Q1	Q2	Q3	Q4	Total
2012	23,215	41,670	-	-	64,886
2011	22,283	41,967	23,870	22,886	111,006
2010	16,870	44,765	29,989	24,922	116,547
2009	13,605	35,161	21,060	15,141	84,966
2008	9,957	30,480	19,574	12,394	72,405
2007	8,990	21,842	17,478	9,549	57,859
2006	10,438	15,572	15,405	12,536	53,952

Herceptin	Q1	Q2	Q3	Q4	Total
2012	25,702	44,628	-	-	70,330
2011	25,089	42,209	31,933	21,812	121,042
2010	23,402	38,555	27,952	25,441	115,350
2009	16,003	32,331	26,830	18,615	93,779
2008	14,092	34,383	28,122	20,282	96,880
2007	19,035	28,188	22,582	14,802	84,608
2006	15,142	19,716	21,557	20,354	76,769

Lucentis	Q1	Q2	Q3	Q4	Total
2012	10,791	27,938	-	-	38,728
2011	8,878	24,313	12,157	10,750	56,099
2010	7,220	19,091	10,841	8,047	45,198
2009	4,621	12,863	8,123	6,152	31,759
2008	3,636	11,060	7,631	4,549	26,876
2007	2,931	6,543	6,579	3,517	19,570
2006	-	-	289	3,335	3,624

Xolair	Q1	Q2	Q3	Q4	Total
2012	5,447	8,609	-	-	14,056
2011	4,590	7,621	5,916	5,823	23,949
2010	3,723	6,386	4,980	4,652	19,741
2009	2,665	5,082	4,085	3,722	15,553
2008	1,488	4,866	3,569	2,927	12,850
2007	1,684	3,942	3,332	2,184	11,142
2006	2,263	2,969	3,041	2,495	10,768

Tysabri	Q1	Q2	Q3	Q4	Total
2012	11,233	12,202	-	-	23,435
2011	9,891	10,796	11,588	11,450	43,725
2010	8,791	8,788	8,735	9,440	35,754
2009	6,656	7,050	7,642	8,564	29,912
2008	3,883	5,042	5,949	6,992	21,866
2007	839	1,611	2,084	2,836	7,370
2006	-	-	-	237	237

Actemra	Q1	Q2	Q3	Q4	Total
2012	1,705	2,074	-	-	3,778
2011	913	1,136	1,401	1,460	4,910
2010	1,587	237	315	688	2,827
2009	585	537	909	1,197	3,228
2008	44	-	146	369	559
2007	32	-	-	17	49
2006	-	-	-	-	-

*** As reported to PDL by its licensees**
Totals may not sum due to rounding

PDL BioPharma, Inc.
Q2-2012
August 2, 2012

Reported Net Sales Revenue by Product ($ in 000's) *

Avastin	Q1	Q2	Q3	Q4	Total
2012	1,502,757	1,573,727	-	-	3,076,484
2011	1,597,461	1,582,705	1,581,095	1,469,994	6,231,255
2010	1,506,788	1,596,892	1,594,707	1,646,218	6,344,605
2009	1,345,487	1,295,536	1,439,730	1,514,053	5,594,806
2008	980,715	1,084,930	1,180,427	1,239,382	4,485,454
2007	678,068	746,587	797,013	875,084	3,096,752
2006	439,318	516,052	570,551	592,897	2,118,817

Herceptin	Q1	Q2	Q3	Q4	Total
2012	1,515,255	1,625,313	-	-	3,140,569
2011	1,391,568	1,559,975	1,642,898	1,432,771	6,027,211
2010	1,270,846	1,349,512	1,300,934	1,409,310	5,330,602
2009	1,210,268	1,133,993	1,226,435	1,278,626	4,849,323
2008	1,105,426	1,195,215	1,211,982	1,186,806	4,699,428
2007	891,761	949,556	979,602	1,015,033	3,835,952
2006	529,585	659,719	761,099	803,576	2,753,979

Lucentis	Q1	Q2	Q3	Q4	Total
2012	1,079,092	1,086,543	-	-	2,165,635
2011	887,757	943,418	1,052,809	1,075,015	3,958,999
2010	721,967	698,890	745,376	804,684	2,970,917
2009	462,103	469,736	555,296	615,212	2,102,347
2008	363,615	393,682	460,167	454,922	1,672,386
2007	224,820	219,579	299,995	322,300	1,066,695
2006	-	-	10,689	157,742	168,431

Xolair	Q1	Q2	Q3	Q4	Total
2012	310,234	314,638	-	-	624,873
2011	267,754	277,642	310,874	314,911	1,171,182
2010	228,859	225,878	251,055	263,389	969,179
2009	184,669	181,086	211,006	219,693	796,454
2008	137,875	169,521	177,179	183,753	668,329
2007	129,172	130,700	144,250	147,754	551,876
2006	95,241	99,354	112,608	118,002	425,204

Tysabri	Q1	Q2	Q3	Q4	Total
2012	374,430	401,743	-	-	776,173
2011	329,696	356,876	388,758	381,618	1,456,948
2010	293,047	287,925	293,664	316,657	1,191,292
2009	221,854	229,993	257,240	285,481	994,569
2008	129,430	163,076	200,783	233,070	726,359
2007	30,468	48,715	71,972	94,521	245,675
2006	-	-	-	7,890	7,890

Actemra	Q1	Q2	Q3	Q4	Total
2012	56,662	66,624	-	-	123,286
2011	30,433	35,370	46,709	48,671	161,183
2010	52,908	5,405	10,493	22,919	91,725
2009	19,504	17,920	30,313	39,888	107,625
2008	1,452	1,377	5,981	12,305	21,115
2007	-	-	-	1,137	1,137
2006	-	-	-	-	-

*** As reported to PDL by its licensees**
Totals may not sum due to rounding

PDL BioPharma, Inc.
Q2-2012
August 2, 2012

Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *

Avastin Sales	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1	2012 - Q2
US Made & Sold	708,539	719,967	688,966	684,878	652,824	724,483
US Made & ex-US Sold	580,981	548,710	587,975	375,830	448,037	532,979
ex-US Made & Sold	307,941	314,028	304,155	409,286	401,896	316,265
Total	1,597,461	1,582,705	1,581,095	1,469,994	1,502,757	1,573,727
US Made & Sold	44%	45%	44%	47%	43%	46%
US Made & ex-US Sold	36%	35%	37%	26%	30%	34%
ex-US Made & Sold	19%	20%	19%	28%	27%	20%

Herceptin Sales	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1	2012 - Q2
US Made & Sold	409,854	442,903	445,395	453,168	456,920	497,109
US Made & ex-US Sold	423,053	642,670	495,086	612,908	523,353	466,477
ex-US Made & Sold	558,661	474,402	702,416	366,695	534,982	661,727
Total	1,391,568	1,559,975	1,642,898	1,432,771	1,515,255	1,625,313
US Made & Sold	29%	28%	27%	32%	30%	31%
US Made & ex-US Sold	30%	41%	30%	43%	35%	29%
ex-US Made & Sold	40%	30%	43%	26%	35%	41%

Lucentis Sales	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1	2012 - Q2
US Made & Sold	378,451	409,674	422,335	428,884	433,428	412,131
US Made & ex-US Sold	509,307	533,745	630,474	646,131	645,665	674,411
ex-US Made & Sold	-	-	-	-	-	-
Total	887,757	943,418	1,052,809	1,075,015	1,079,092	1,086,543
US Made & Sold	43%	43%	40%	40%	40%	38%
US Made & ex-US Sold	57%	57%	60%	60%	60%	62%
ex-US Made & Sold	0%	0%	0%	0%	0%	0%

Xolair Sales	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1	2012 - Q2
US Made & Sold	164,621	167,608	184,837	188,728	185,505	193,600
US Made & ex-US Sold	-	-	-	-	-	-
ex-US Made & Sold	103,133	110,034	126,037	126,184	124,729	121,039
Total	267,754	277,642	310,874	314,911	310,234	314,638
US Made & Sold	61%	60%	59%	60%	60%	62%
US Made & ex-US Sold	0%	0%	0%	0%	0%	0%
ex-US Made & Sold	39%	40%	41%	40%	40%	38%

Total Sales	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1	2012 - Q2
US Made & Sold	1,661,465	1,740,152	1,741,534	1,755,657	1,728,678	1,827,323
US Made & ex-US Sold	1,513,340	1,725,125	1,713,535	1,634,869	1,617,054	1,673,867
ex-US Made & Sold	969,735	898,464	1,132,608	902,165	1,061,607	1,099,031
Total	4,144,540	4,363,741	4,587,677	4,292,691	4,407,339	4,600,221
US Made & Sold	40%	40%	38%	41%	39%	40%
US Made & ex-US Sold	37%	40%	37%	38%	37%	36%
ex-US Made & Sold	23%	21%	25%	21%	24%	24%

*** As reported to PDL by its licensees**
Totals may not sum due to rounding